KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Operating Expenses (2020 - 2026)

AbCellera Biologics filings provide 7 years of Operating Expenses readings, the most recent being $65.8 million for Q1 2026.

  • Quarterly Operating Expenses fell 1.59% to $65.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $291.2 million through Mar 2026, down 15.76% year-over-year, with the annual reading at $292.2 million for FY2025, 14.95% down from the prior year.
  • Operating Expenses hit $65.8 million in Q1 2026 for AbCellera Biologics, down from $73.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $100.8 million in Q2 2024 and bottomed at $54.3 million in Q2 2022.
  • Average Operating Expenses over 5 years is $73.3 million, with a median of $66.9 million recorded in 2025.
  • The largest annual shift saw Operating Expenses skyrocketed 105.14% in 2022 before it tumbled 33.85% in 2025.
  • AbCellera Biologics' Operating Expenses stood at $59.3 million in 2022, then grew by 26.82% to $75.2 million in 2023, then rose by 3.42% to $77.8 million in 2024, then dropped by 5.62% to $73.4 million in 2025, then dropped by 10.35% to $65.8 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Operating Expenses are $65.8 million (Q1 2026), $73.4 million (Q4 2025), and $85.2 million (Q3 2025).